General Oncology secured $10.88 million to develop treatments for BRCA-related metastatic pancreatic cancer using multi-agent chemotherapy regimens supported by stem cell transplants to improve patient outcomes.
General Oncology secured $10.88 million to develop treatments for BRCA-related metastatic pancreatic cancer using multi-agent chemotherapy regimens supported by stem cell transplants to improve patient outcomes.
